Clinical Trial Finder

Inclusion Criteria:

1. Age greater than or equal to 18 years old, male or female; 2. Relapsed or refractory CNS-involved large b-cell lymphoma after at least first-line therapy, with an efficacy assessment of CR or PR after salvage therapy, and current stable efficacy status; 3. Eastern Cooperative Oncology Group (ECOG) score of 0-2; 4. Have a life expectancy of ≥ 12 weeks. 5. Use contraception. 6. Have adequate bone marrow and organ function: 1. Neutrophil count (anc) ≥1.0 x 109/L; 2. Hemoglobin ≥ 8.0 g/dl; 3. Platelet count ≥ 50 x 109/L; 4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN) 5. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 x ULN or ≤ 5 x ULN (in the presence of hepatic invasion); 6. Creatinine clearance ≥40mL/min. 7. Lipase ≤ 1.5 x ULN.

Exclusion Criteria:

1. Severe active central nervous system symptoms. 2. Prior chimeric antigen receptor cellular immunotherapy targeting cd19. 3. Known human immunodeficiency virus (hiv) infection or positive immunoassay; 4. Live vaccination within 30 days prior to study drug administration; 5. Active autoimmune disease requiring systemic therapy in the last 12 months. 6. Allergy to the study drug or history of severe allergic reactions. 7. Potential risk of malignant cardiac arrhythmia. 8. History of stroke or intracranial hemorrhage within 3 months prior to the date of administration of study medication. 9. Other malignant tumors presently or within 3 years prior to enrollment. 10. Conditions that, in the judgment of the investigator, would interfere with full participation in the study; pose a significant risk to the subject; or interfere with the interpretation of the study data. 11. Pregnant or lactating patients;

Arms

Experimental: intervention group

Relma-cel Followed by Tislelizumab

Interventions

Drug: - Relma-cel Followed by Tislelizumab

Enrolled patients with relapsed/refractory (R/R) CNSL will receive Relma-cel infusion, followed by treatment with Tislelizumab (200mg, IV, q4w, for 12 months) starting at 35 days post-infusion. BTK inhibitors will be used in combination as needed.